APPLICATION
NDA012928
TYPE
NDA
ORIGINAL APPROVAL
1962-03-21
LATEST ACTION
1981-06-09
ROUTE
ORAL
DOSAGE FORM
CAPSULE, SUSPENSION
MARKETING STATUS
Discontinued
Products
NOVRADDiscontinued
LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS EQ 50MG BASE · CAPSULE · ORAL
NOVRADDiscontinued
LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS EQ 100MG BASE · CAPSULE · ORAL
NOVRADDiscontinued
LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS EQ 50MG BASE/5ML · SUSPENSION · ORAL
Approval history
1981-06-09Labeling · Supplement 12AP
1980-03-11Manufacturing (CMC) · Supplement 11 · standardAP
1978-02-17Labeling · Supplement 10AP
1976-08-24Manufacturing (CMC) · Supplement 9 · standardAP
1976-08-24Manufacturing (CMC) · Supplement 8 · standardAP
1976-08-23Manufacturing (CMC) · Supplement 7 · standardAP
1972-05-08Labeling · Supplement 2AP
1962-03-21Type 3 - New Dosage Form · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.